169 related articles for article (PubMed ID: 22228356)
1. F-18 FDG and C-11 methionine PET/CT in intracranial dural metastases.
D'Souza MM; Jaimini A; Tripathi M; Garg N; Sharma R; Monndal A; Tripathi RP
Clin Nucl Med; 2012 Feb; 37(2):206-9. PubMed ID: 22228356
[TBL] [Abstract][Full Text] [Related]
2. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
3. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
5. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors.
Kitajima K; Nakamoto Y; Okizuka H; Onishi Y; Senda M; Suganuma N; Sugimura K
Ann Nucl Med; 2008 Aug; 22(7):595-602. PubMed ID: 18756362
[TBL] [Abstract][Full Text] [Related]
8. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
9. Dural MALT Lymphoma Detected by 11C-Methionine PET/CT.
Annunziata S; Cuccaro A; Caldarella C; Hohaus S
Clin Nucl Med; 2017 Dec; 42(12):962-963. PubMed ID: 28902730
[TBL] [Abstract][Full Text] [Related]
10. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric muscle activity on (18)F-FDG PET/CT.
Palard X; Carai S; Le Roux PY; Salaün PY; Abgral R
Clin Nucl Med; 2015 Jun; 40(6):e336-7. PubMed ID: 25706792
[TBL] [Abstract][Full Text] [Related]
12. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer?
Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
14. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
16. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
17. F-18 fluorodeoxyglucose PET/CT and post hoc PET/MRI in a case of primary meningeal melanomatosis.
Lee HJ; Ahn BC; Hwang SW; Cho SK; Kim HW; Lee SW; Hwang JH; Lee J
Korean J Radiol; 2013; 14(2):343-9. PubMed ID: 23483049
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT in a Case of Dural Amyloidoma.
Ran P; Liu Y; Liang X; Zhang Y; Dong A
Clin Nucl Med; 2018 Dec; 43(12):925-929. PubMed ID: 30300204
[TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
20. A case of primary leptomeningeal melanoma evaluated on FDG PET/CT.
Golden MJ; Wheir WH; Katzman J; Turk ZA; Hartshorne MF
Clin Nucl Med; 2011 Oct; 36(10):919-21. PubMed ID: 21892047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
